β Scribed by Jeffrey J. Brown; Rita M. Kristy; Gary R. Stevens; Joseph A. Pierro
No coin nor oath required. For personal study only.
To describe and summarize the safety data from the OptiMARK clinical development program.
In the 18 clinical studies comprising the clinical program, doses ranging from 0.1 to 0.7 mmol/kg were administered to healthy adult volunteers, patients with hepatic or renal impairment, and patients with confirmed or highly suspected central nervous system (CNS), liver, breast, vascular, bone, or soft tissue pathologies. A total of 2038 injections of OptiMARK, Magnevist, or placebo were administered to 1684 subjects. Safety assessments were performed at appropriate intervals during all Phase 1, 2, and 3 studies.
Of the 1684 subjects exposed to a study drug or placebo in the clinical development program, 646 subjects experienced 1293 adverse events. Thirtyβone percent of the OptiMARK injections were associated with an adverse event. In comparison, 35% of Magnevist injections and 48% of placebo injections were associated with at least one adverse event.
OptiMARK was safe and wellβtolerated with a safety profile similar to that of Magnevist. J. Magn. Reson. Imaging 2002;15:446β455. Β© 2002 WileyβLiss, Inc.
π SIMILAR VOLUMES